BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 23583193)

  • 61. The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways.
    Meng J; Zhang HH; Zhou CX; Li C; Zhang F; Mei QB
    Oncol Rep; 2012 Jul; 28(1):384-8. PubMed ID: 22552631
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
    Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
    Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
    Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
    Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
    [TBL] [Abstract][Full Text] [Related]  

  • 64. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc.
    Wang LG; Liu XM; Fang Y; Dai W; Chiao FB; Puccio GM; Feng J; Liu D; Chiao JW
    Int J Oncol; 2008 Aug; 33(2):375-80. PubMed ID: 18636159
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
    Duo J; Ma Y; Wang G; Han X; Zhang C
    DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of histone deacetylase on prostate carcinoma.
    Zhang Y; Xu Q; Liu G; Huang H; Lin W; Huang Y; Chi Z; Chen S; Lan K; Lin J; Zhang Y
    Int J Clin Exp Pathol; 2015; 8(11):15030-4. PubMed ID: 26823840
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
    Rokhlin OW; Glover RB; Guseva NV; Taghiyev AF; Kohlgraf KG; Cohen MB
    Mol Cancer Res; 2006 Feb; 4(2):113-23. PubMed ID: 16513842
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
    Cheng YW; Liao LD; Yang Q; Chen Y; Nie PJ; Zhang XJ; Xie JJ; Shan BE; Zhao LM; Xu LY; Li EM
    Cell Biochem Funct; 2018 Dec; 36(8):398-407. PubMed ID: 30484863
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
    Karthik S; Sankar R; Varunkumar K; Ravikumar V
    Biomed Pharmacother; 2014 Apr; 68(3):327-34. PubMed ID: 24485799
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.
    Sun JY; Wang JD; Wang X; Liu HC; Zhang MM; Liu YC; Zhang CH; Su Y; Shen YY; Guo YW; Shen AJ; Geng MY
    Acta Pharmacol Sin; 2017 Apr; 38(4):551-560. PubMed ID: 28112184
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
    Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
    BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A.
    Rashid SF; Moore JS; Walker E; Driver PM; Engel J; Edwards CE; Brown G; Uskokovic MR; Campbell MJ
    Oncogene; 2001 Apr; 20(15):1860-72. PubMed ID: 11313934
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
    Yang B; Yu D; Liu J; Yang K; Wu G; Liu H
    Tumour Biol; 2015 Jul; 36(7):5051-61. PubMed ID: 25649979
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.
    Asgar MA; Senawong G; Sripa B; Senawong T
    Int J Oncol; 2016 Jan; 48(1):409-20. PubMed ID: 26575528
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity.
    Kang KA; Piao MJ; Kim KC; Zheng J; Yao CW; Cha JW; Kim HS; Kim DH; Bae SC; Hyun JW
    Int J Oncol; 2013 Dec; 43(6):1907-14. PubMed ID: 24100442
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
    Bao L; Diao H; Dong N; Su X; Wang B; Mo Q; Yu H; Wang X; Chen C
    Cell Biol Toxicol; 2016 Dec; 32(6):469-482. PubMed ID: 27423454
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
    Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
    Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
    Feng X; Han H; Zou D; Zhou J; Zhou W
    Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells.
    Yang X; Zhang N; Shi Z; Yang Z; Hu X
    Mol Med Rep; 2015 Apr; 11(4):2908-12. PubMed ID: 25501628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.